Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors
Shapiro, G. I. Basu, B. El-Khoueiry, A. Postel-Vinay, S. Im, S. A. Rha, S. Y. Friedman, C. F. Italiano, A. Kim, Y. M. Lim, M. C.
Shapiro, G. I.
Basu, B.
El-Khoueiry, A.
Postel-Vinay, S.
Im, S. A.
Rha, S. Y.
Friedman, C. F.
Italiano, A.
Kim, Y. M.
Lim, M. C.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Shapiro GI, Basu B, El-Khoueiry A, Postel-Vinay S, Im SA, Rha SY, et al. Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors. Cancer Research. 2022 Jun;82(12). PubMed PMID: WOS:000892509502114.